Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
76.33
-1.87 (-2.39%)
Jan 23, 2026, 4:00 PM EST - Market closed
Disc Medicine Employees
Disc Medicine had 142 employees as of September 30, 2025. The number of employees increased by 60 or 73.17% compared to the same quarter last year.
Employees
142
Change
60
Growth
73.17%
Revenue / Employee
n/a
Profits / Employee
-$1,275,423
Market Cap
2.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 142 | 60 | 73.17% | 142 | 0 |
| Jun 30, 2025 | 125 | 47 | 60.26% | 125 | 0 |
| Mar 31, 2025 | 94 | 16 | 20.51% | 94 | 0 |
| Dec 31, 2024 | 84 | 10 | 13.51% | 84 | 0 |
| Sep 30, 2024 | 82 | 22 | 36.67% | 82 | 0 |
| Jun 30, 2024 | 78 | 23 | 41.82% | 78 | 0 |
| Mar 31, 2024 | 78 | 27 | 52.94% | 78 | 0 |
| Dec 31, 2023 | 74 | 28 | 60.87% | 74 | 0 |
| Sep 30, 2023 | 60 | 22 | 57.89% | 60 | 0 |
| Jun 30, 2023 | 55 | 17 | 44.74% | 55 | 0 |
| Mar 31, 2023 | 51 | 13 | 34.21% | 51 | 0 |
| Dec 31, 2022 | 46 | - | - | 46 | 0 |
| Jun 30, 2022 | 38 | - | - | 37 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 710 |
| Arcus Biosciences | 627 |
| Adaptive Biotechnologies | 619 |
| Tarsus Pharmaceuticals | 323 |
| Dyne Therapeutics | 240 |
| Catalyst Pharmaceuticals | 181 |
| Viridian Therapeutics | 143 |
| IDEAYA Biosciences | 131 |
IRON News
- 9 days ago - Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action - Benzinga
- 10 days ago - Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - GlobeNewsWire
- 13 days ago - Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 - GlobeNewsWire
- 20 days ago - Disc Medicine: RALLY-MF Data Validates Pipeline Optionality - Seeking Alpha
- 7 weeks ago - Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript - Seeking Alpha
- 7 weeks ago - Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha